-
ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma
The rapid emergence of CAR-T cell therapies and bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), leading to substantial improvements in patient outcomes. However, limitations related to accessibility, treatment costs, manufacturing complexity, and toxicity management continue to restrict their widespread use. As a result, there remains a pressing need for innovative…
-
ASCO 2026 Voices from China | Haiwen Huang: New Frontiers in Frontline Lymphoma Optimization and Precision Treatment for Special Patient Populations
As part of its special ASCO 2026 coverage series, “China Perspectives at ASCO,” Oncology Frontier – Hematology Frontier invited leading Chinese experts to interpret the most practice-changing research presented at this year’s meeting and discuss its relevance to clinical practice in China.
-
ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS
Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.
-
ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL
The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence…
-
ASCO China Voice | From Post–CAR-T Relapse to Treatment Redesign: Director Yajing Zhang’s Team Reports Exploratory Results of Sequential Multi-Antigen CAR-T Therapy in B-Cell Lymphoma
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is currently underway in Chicago, bringing together oncology experts from around the world to showcase the latest advances in cancer research and treatment.
-
ASCO China Voice | From Post–CAR-T Relapse to Treatment Redesign: Director Yajing Zhang’s Team Reports Exploratory Results of Sequential Multi-Antigen CAR-T Therapy in B-Cell Lymphoma
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is currently underway in Chicago, bringing together oncology experts from around the world to showcase the latest advances in cancer research and treatment.
-
CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session
The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual…
-
CGOG 2026 Day 3 | ASCO Precision Oncology and Novel Therapeutics Highlights Session
On June 11, the online program of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting continued with a dedicated session, “ASCO Highlights: Precision Oncology and Novel Therapeutics.” The session was livestreamed across multiple platforms and attracted more than 15,000 online viewers.
Connecting Medical Expertise through Media